Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: National Tuberculosis Control Programme,
Street 1: Community Health Sciences Unit
Street 2: P/Bag 65,
City: Lilongwe
Province: Central region
Post Code: 0000
Country: Malawi
Phone: 2651753612/ 265 1 757680
Email: idambe@ntpmalawi.org
Web Site:

Focal Point Contact Information

Salutation: Mr
First Name: Isaias
Last Name: Dambe
Title: Deputy Programme Manager
Email: ildambe@yahoo.com
Phone: 265 1757680 / 265 1 753 612

Alternate Focal Point Contact Information

Salutation: Mr.
First Name: Austin
Last Name: Makwakwa
Title: IEC Officer
Email: a_makwakwa@yahoo.com
Phone: 265 999 274 228

General Information

Board Constituency: Countries
Organization Type - Primary: Governmental Organization
Organization Type - Secondary: None
Is your organization legally registered in your country: Yes
Organization Reach: National
Organization Description:
A government department responsible for tuberculosis control activities, including registration, treatment, management, data analysis, training and technical guidance.
It is also the responsible for policy formulation, guidance as well as sourcing funding to run TB Control activities in the country

It is the organisation mandated by the Government of Malawi to oversee, direct and advocate for TB control activities.
The organization's plans are to enhance DOTS in all the corners of the country (there is already 100% coverage), to control the development and spread of multi-drug resistant TB and reduce TB/HIV co-infection and promote involvement of other stakeholders.
 
Total number of staff in your organization: 100 +
Number of full-time staff who are directly involved with TB: 100 +
Number of part-time staff who are directly involved with TB: 100 +
Number of volunteers who are directly involved with TB: 100 +
 
What is your organization's annual budget (USD) dedicated to TB? $1 MIL-$10 MIL
How did you hear about the Stop TB Partnership: Attendance at a TB related event
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Resource mobilization
 
Are you a member of a Stop TB national partnership: Malawi
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
Involves all stakeholders in the generation of the strategic plan
 

Geographical Reach

Which country is your headquarters located in: Malawi
Which WHO region is the main focus of your work: African
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Malawi

Specializations

Advocacy
Delivery of health services and care
Funding, including innovative and optimized approach to funding TB Care
Provision of drugs, diagnostics and commodities
Research and Development

Specializations in Countries

Delivery of health services and care Malawi

Contribution

Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

TB Care Delivery:
Since 1990, the country has adapted and adopted DOTS programme and strategies as advanced by the WHO. Since 1984 it has provided data on DOTS centres as they have been expanded from the then 25 to the current 120. In 2006 it adapted a WHO approach of development of an IEC Strategic Plan for expansion of DOTS.

Drug-Resistant TB:
Since 2007 it has provided data to WHO on yearly bases for the surveillance of MDR-TB in Malawi. It carried out a DR-Survey in Malawi in 2010 in order to determine the magnitude of the problem.

TB-HIV:
In 2008, the NTP developed a TB/HIV collaborative activities plan as advocated by WHO in order to ensure adherence to standards. It provides to WHO yearly data on TB/HIV co-infection in order to monitor treands. It conducted baseline co-infection survey in 2000 and has since routinely reported on TB/HIV coinfection. In 2008 it produced guidelines for TB/HIV collaboration for implementation of the 12 recommended areas of collaboration.

Laboratory Strengthening:
The NTP has contributed towards the expansion of TB laboratory microscopy and following the WHO guidelines on TB laboratory work. It provides guidance and SOPs for laboratory workers. It trains laboratory workers on standard TB microscopy.

New Diagnostics:
In 2010 it introduced the MIGT-960 for the culture and drug sensitivity testing of TB in order to monitor the DR-TB.
In 2011 the NTP introduced the Gene-Expert for rapidly diagnosing TB as well as the estimating Rifampicin resistant in TB/HIV co-infect patients. It is currently being rolled out. In 2011 it also introduced the LED light and Flourecent microscope for the diagnosis of TB in high burden laboratories.

New TB Drugs:
The NTP intends to take part part in any trials involving the development and testing of new TB drugs as and when approved by the WHO in the future.

New TB Vaccines:
It will take part in any WHO approved vaccine trials as and when the research is approved.

Fundamental Research:
It will take part in fundamental research approved by the WHO.

Research:
Between 1996 and 2009 the NTP undertook extensive operational research studies which have influenced policy both locally and internationally.

Declaration

Declaration of interests:
none

Application date:  
Last updated: July 22, 2013